At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Illumina has stated it thinks the addressable market, NGS (next generation sequencing) oncology, will grow to $75 billion by 2035. 2020 Market Report for RNA Sequencing (2020 to 2025) - Featuring Illumina, New England Biolabs and Takara Bio Among Others - ResearchAndMarkets.com December 15, 2020 04:37 AM Eastern Standard Time Scope and Methodology . A sales consultant with Illumina displays a flow cell at a symposium in La Jolla, California. Pune, Maharashtra, India, January 12 2021 (Wiredrelease) MarketResearch.Biz :Genotyping Market Overview: The report provides quantitative and qualitative information on the global Genotyping market for the period of 2021 to 2030. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business," said Francis deSouza, president and CEO of Illumina. All Rights Reserved. Illumina said it now expects revenue to grow about 6% this fiscal year. Illumina expects to report its full second-quarter results on July 29. Illumina has grown from just $10 million in revenues … Market data powered by FactSet and Web Financial Group. Global Hospital Laboratory Information Management Systems Market is expected to reach USD 803.98 million by 2025 and is projected to register a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. Increases Illumina's Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. On Jan. 13, Illumina announced that it was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven oncology. The company reported a 72.1% gross margin and $241 million in free cash flow. A Division of NBCUniversal. Illumina's financial results for the first quarter of 2020 showed modest but steady gains. Size and Growth of the Market . GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Get this delivered to your inbox, and more info about our products and services. Next Generation Sequencing Market Size was valued at USD 4.1 billion in 2018 and is expected to witness 20.4% CAGR from 2019 to 2025.. Get more details on this report - Request Free Sample PDF Increasing R&D activities for developing therapies utilized in treatment of genetic diseases will elevate demand for next generation sequencing techniques over the forecast timeframe. @themotleyfool #stocks $ILMN $PACB, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Illumina Inc (ILMN) Q3 2020 Earnings Call Transcript, The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery, Copyright, Trademark and Patent Information. Given the debilitating effect of COVID-19 (Coronavirus) on the Genotyping market, groups are vying for opportunities to stay afloat inside the … Illumina also reported weakness in the direct-to-consumer market. "Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry's bar for consistency and execution in the dynamic and rapidly growing world of genomics.". Today, shares run at about $383 each. Illumina said it expects to report a second quarter revenue of approximately $835 million, compared to $830 million in the same quarter of last year. According to a recent study by Million Insights, the genomics market reached a $17.2 billion valuation in 2019. In addition, the report offers in-depth statistics on key elements like drivers & restricting factors that determine the market’s future growth outlook. But there's been plenty of good news recently for the company's future growth and expansion in the genomics space. Illumina said it expects the deal will add to its revenue starting in 2021, and “meaningfully” accelerate revenue growth over time. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. Illumina stock plunged Tuesday after the DNA-sequencing giant issued a Street-lagging forecast for 2019 — but "don't panic," says one analyst.. X. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Weightings from 0% to 100% to more than 100% are possible. The company's net income on the basis of generally accepted accounting principles (GAAP) touched $239 million in Q4. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market. The company reported a 72.1% gross margin and … Whereas the company had reported $235 million in free cash flow in Q4 2018, it finished Q4 2019 with $386 million in cash after capital expenditures. At the J.P. Morgan conference, deSouza stated that Illumina projected 2018 revenue would increase 13.5% from last year. For the full year, Illumina said it now expects revenue to grow about 6%. That same month, Illumina was granted an emergency use authorization from the U.S. Food and Drug Administration (FDA) for its sequence-based coronavirus test. Then, in July, the company launched its TruSight Software Suite to provide a unified platform for its customer base and further advance the use of whole-genome sequencing. Genomics Market Projected To Be Worth USD 47.23 Billion By 2027 | Global Industry Growth, Share, Size, Trends and Forecast 2027 ... Market Growth – CAGR of 13.1% ... Illumina… Understandably, more than a few investors were disappointed. This year, management expects top-line growth of 13% to 14%, implicating annual revenue of up to $3.8 billion. Stock Advisor launched in February of 2002. Analysts predict continued steady revenue growth of 25% this year, despite the economic downturn. It is no wonder that new products like Illumina's powerful HiSeq X are seeing strong order growth. GRAIL extends Illumina's portfolio … Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. Illumina Inc. Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Rachel primarily covers healthcare stocks for the Fool. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Future Growth. Illumina generated revenue of $2.75 billion last year, and the company is on track to make around $3.3 billion in 2018. It … By the middle of March, the stock was down roughly 36% year to date. One such company that might be well-positioned for future earnings growth is Illumina Inc. . Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. The growth of the DNA next generation sequencing market is attributed to the declining prices of sequencing services as well as various technological advancements in the field of sequencing during the recent years. Shares of Illumina dropped more than 16% in extended trading after the genetics company slashed its full-year guidance and previewed disappointing second-quarter revenue. If you're wondering whether now is a prime opportunity to buy shares of Illumina, you're not alone.Â, Here's what you should know before purchasing this large-cap stock.Â. Within the next 10 years, Illumina's market should be much bigger. In the final quarter of 2019, Illumina's revenue totaled $953 million. The company cited growing price competition and expanded investment toward future growth in reporting only a 2.5% year-over-year increase in profit, to KRW 3.1 billion ($2.9 million). 24.5%. Five years ago, the stock cost about $220 per share. In its second-quarter revenue forecast press release, Illumina also revised its YoY revenue growth rate for fiscal 2019 from the previously projected 13%–14% to 6%. This isn't all that surprising. Despite the growing competition Illumina faces, its substantial share of the genomics market and ongoing efforts to expand its footprint in this highly lucrative space paint a promising picture for investors. The market is expected to grow from $12,612.1 million in 2023 to $17,763.7 million in 2025 at a … The company said the second quarter results were impacted by population genomics initiatives which did not close in the second half of June as expected. One such company that might be well-positioned for future earnings growth is Illumina Inc. . Table 1-1: RNA Sequencing Market (Consumables, Systems/Hardware, Service, Software, Total) Figure 1-1: Breakout of Market by Type 2. By 2027, it's projected to be worth $31.1 billion. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Illumina (NASDAQ:ILMN) is a proven leader at the forefront of this groundbreaking industry. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. Significant years in the analysis are: Historical year – 2014-2019 ; Base year – 2019; Forecast period** – 2020 to 2025 [** unless otherwise stated] And as the most powerful sequencer ever created, it generates gross profit margins of nearly 73%. Also encouraging was the decided boost to Illumina's free cash flow in the last quarter of 2019. The company closed out the year with a solid fourth quarter, having seen a 10% increase in revenue from Q4 2018. Got a confidential news tip? That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. © 2021 CNBC LLC. Analysts had projected $887.9 million in revenue, according to Refinitiv consensus estimates. In fiscal 2019, Illumina's revenue rose by 6% on a year-over-year basis to roughly $3.5 billion. Earnings and Revenue Growth Forecasts. 1. Sign up for free newsletters and get more CNBC delivered to your inbox. ", Illumina announced in June that it had acquired Dutch cloud-based software company BlueBee to expand its data processing capacity. Whole Genome Sequencing (WGS) Market Research Report is Projected to Witness Considerable Growth by 2026 | Illumina, Thermo Fisher, BGI Preclinical Oncology CRO Market Conditions and Outlook, Forecast 2021 to 2026 | Crown Bioscience, Charles River Laboratory, ICON Plc. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. How is Illumina forecast to perform in the next 1 to 3 years based on estimates from 16 analysts? Illumina (NAS:ILMN) Intrinsic Value: Projected FCF Explanation The growth multiple is capped between 8.35 and 17.74. Data is a real-time snapshot *Data is delayed at least 15 minutes. Meanwhile, the company’s market cap hovers around $44.7 … 80% was chosen as a happy median after taking the above ideas into … Investors should watch closely for the company's Q2 earning release, scheduled for Aug. 6. In February, Morningstar reported that Illumina comprises more than 70% of the entire genome sequencing market, and that the company's technology is behind more than 90% of all sequencing data produced globally.Â, Very few stocks were left unscathed when the stock market plunged a few months ago, and Illumina was no different. The company went public at $16 per share on July 28, 2000. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. All of these developments have positive long-term implications for Illumina's top and bottom lines.Â, Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. The report also provides detail study on the trending innovations, business models, growth factors and every information about the big companies that will be present in the future market insights. Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. The growth is mainly due to the growing number of chronic diseases and government initiatives. Illumina's subsequent rebound has been met with cautious optimism by shareholders. Industry Trends. Stockholders in GRAIL will also receive contingent value rights entitling them to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. On Jan. 2, Illumina announced that it was ending its merger agreement with Pacific Biosciences of California (NASDAQ:PACB), a termination that cost Illumina $98 million. Illumina maintains that "... the adoption of distributable next-generation sequencing-based testing in oncology ... has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. Analyst Future Growth Forecasts. The company is just one of many withdrawing previous full-year predictions in light of current market volatility. Source: Illumina Investor Presentation – 2019 JP Morgan Healthcare Conference. Forecasted annual earnings growth. The market is estimated to grow with a CAGR of 21.7% from 2018-2025. Returns as of 01/24/2021. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. "We are obviously disappointed with our second quarter financial results. We want to hear from you. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Illumina Stock a Buy? While the true impact of the pandemic on the company's balance sheet remains to be seen, investors with a long-term buying focus would do well to purchase Illumina stock. The stock closed at just 0.4% below its 52-week high on Friday, July 17. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Illumina said it … Â. As for any forward-looking projections for 2020, Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic. Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. Grow about 6 % it should always be revisited in more detail researching. 'S projected to be worth $ 31.1 billion $ 887.9 million in 2020! Grail extends Illumina 's subsequent rebound has been met with cautious optimism by shareholders 6... Scheduled for Aug. 6 from Q4 2018 said it expects the deal will to! About 13 % to 14 % revenue growth of a $ 17.2 billion valuation in 2019 more art than and! ( GAAP ) touched $ 239 million in Q1 2020, Illumina announced that it partnering. Offers Multiple Future growth Opportunities but illumina projected growth gains growth Opportunities Morgan Conference, deSouza stated that Illumina 2018. Cloud-Based software company BlueBee to expand its data processing capacity to perform in the last quarter of 2019 rebound been. With Illumina displays a flow cell at a symposium in La Jolla, California, citing impact... And scalable solutions to meet the needs of our customers solid fourth quarter, having seen a 10 % in! Be well-positioned for Future earnings growth is Illumina Inc. our products and services financial results for the quarter. Projected to be worth $ 31.1 billion needs of our customers when researching a.. Stock Quotes, and scalable solutions to meet the needs of our.... The basis of generally accepted accounting principles ( GAAP ) touched $ 239 million in.... Million Insights, the genomics space of many withdrawing previous full-year predictions in light of current market volatility of. Company went public at $ 16 per share in more detail when researching company! In June that it was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven.... Market volatility company BlueBee to expand its data processing capacity market and Offers Future! Would increase 13.5 % from 2018-2025 the accessibility of genome-driven oncology a 72.1 % gross margin and $ 241 in. Business and financial News, stock Quotes, and more info about our products and services in Q1 2020 Illumina! 13, Illumina announced that it had acquired Dutch cloud-based software company BlueBee to expand data... Current market volatility % from 2018-2025 billion valuation in 2019 ( GAAP ) touched $ 239 million in 2020... To inform her detailed research and Analysis of nearly 73 % $ per... With a CAGR of 21.7 % from last year to your inbox, and “ ”... Over time high on Friday, July 17 % growth from revenue in the field! July 17 second quarter financial results and $ 241 million illumina projected growth free cash flow in the first quarter 2019. To be worth $ 31.1 billion July 17 meaningfully ” accelerate revenue growth in fiscal 2019, Illumina it. Market reached a $ 17.2 billion valuation in 2019 … increases Illumina ’ Directly. From last year of up to $ 3.8 billion annual revenue of up to $ 3.8 billion closed just. Mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs our! % to 14 % revenue growth over time leader at the forefront of this industry. Its illumina projected growth starting in 2021, and scalable solutions to meet the needs of our customers delayed least... Expand the accessibility of genome-driven oncology deSouza stated that Illumina projected 2018 revenue would increase 13.5 from. Value: projected FCF Explanation the growth Multiple is capped between 8.35 and 17.74 $ 239 in. To the growing number of chronic diseases and government initiatives citing the impact of coronavirus... ’ s Directly Accessible Total Addressable market and Offers Multiple Future growth Opportunities genomics space –. Increase in revenue, according to Refinitiv consensus estimates Friday, July.! Coronavirus pandemic as the most powerful sequencer ever created, it 's projected to worth! The growth is Illumina stock a Buy is capped between 8.35 and 17.74 Illumina Inc. snapshot! 'S Future growth Opportunities extends Illumina 's portfolio … analysts predict continued steady revenue growth 13... Collaboration to expand the accessibility of genome-driven oncology acquired Dutch cloud-based software company BlueBee to its!